Quality management in hemodialysis;Gestión de calidad en hemodiálisis

Nefrologia

Volumn 26, Issue SUPPL.8, 2006, Pages 73-87

  Angoso, M ^a   Alcalde, G ^a   Alvarez Ude F ^a   Arenas, M D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; STANDARD; TOTAL QUALITY MANAGEMENT;

HUMANS; RENAL DIALYSIS; TOTAL QUALITY MANAGEMENT;

EID: 38449122656     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Real Decreto 1277/2003, de 10 de octubre, por el que se establecen las bases generales sobre autorización de centros, servicios y establecimientos sanitarios. BOE 23/10/2003.
2. Arenas MD, Gil MT, Egea JJ, Sirvent AE, Giménez A. Aseguramiento de la calidad y certificación de una unidad de hemodiálisis según normas ISO-9001-2000. Nefrología 23: 37-46, 2003.
3. Guía para la gestión de procesos. Osakidetza-Servicio vasco de salud. Vitoria, 1997.
4. López Revuelta K, Lorenzo S, Gruss E, Garrido MV, Moreno JA. Aplicación de la gestión por procesos en nefrología. Gestión del proceso hemodiálisis. Nefrología 22: 329-39, 2002
5. Sistemas de gestión de la calidad. Directrices para la mejora de los procesos en las organizaciones sanitarias. UNE 66924 IN. AENOR. Madrid, 2002.
6. a edición. AENOR. Madrid, 2001.
7. Guía de gestión por procesos e ISO 9001: 2000 en las organizaciones sanitarias. Osakidetza-Servicio vasco de salud. Vitoria, 2004.
8. Guía de evaluación EFQM para unidades de gestión. Osakidetza-Servicio vasco de salud. Vitoria, 2004.
9. Álvarez-Ude F, Amoedo ML, Egea JJ, et al Impacto del seguimiento de indicadores de calidad en hemodiálisis. Nefrología 24: 261-75, 2004.
10. Khan IH, Catto GR, Edward N, Fleming LW, Henderson IS, MacLeod AM: Influence of coexisting disease on survival on renal-replacement therapy. Lancet 341: 415-418, 1993.
11. Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 47: 1245- 1251, 1994.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383, 1987.
13. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML: A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 108: 609-613, 2000.
14. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 14 (Supl. 5): 1-50, 1999
15. Haemodialysis TEEGo: Nephrol Dial Transplant 17 (Supl. 7), 2002.
16. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 94-111, 2004.
17. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ: Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19: 898-903, 2004.
18. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ: Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62: 2167- 2175, 2002.
19. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 (Supl. 2): ii1-47, 2004.
20. Roger SD, Cooper B: What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology (Carlton) 9: 223-228, 2004
21. Pereira AA, Sarnak MJ: Anemia as a risk factor for cardiovascular disease. Kidney Int (Supl.): S32-39, 2003.
22. Owen WF, Jr. et al National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. Am J Kidney Dis 34 (4 Supl. 2), pp. S5-S11, 1999.
23. Cavill I: Iron status as measured by serum ferritin: the marker and its limitations. Am J Kidney Dis 34(4 Supl. 2): S12- 7:[1], 1999.
24. Kalantar-Zadeh K, Rodríguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19 (1), pp. 141-9, 2004.
25. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 4: 1205-1213, 1993.
26. I. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: update 2000. Am J Kidney Dis 37: S7-S64, 2001.
27. European Best Practice Guidelines for Haemodialysis (Part I) Haemodialysis adequacy. Nephrol Dial Transplant 17: 16-31, 2002.
28. Cooper BA, Penne EL, Bartlett LH, Pollock CA: Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 43: 61-66, 2004.
29. Steinman TI: Serum albumin: its significance in patients with ESRD. Semin Dial 13: 404-408, 2000.
30. Rodríguez Hernández JA, González Parra E, Gutiérrez Julián JM et al Guías de acceso vascular en hemodiálisis. Nefrología 25 (Supl. 1), 2005.
31. Rodríguez Hernández JA, López Pedret J, Piera L: Vascular access in Spain: analysis of its distribution, morbidity, and monitoring systems. Nefrología 21: 45-51, 2001.
32. Elseviers MM, Van Waeleghem JP: Identifying vascular access complications among ESRD patients in Europe. A prospective, multicenter study. Nephrol News Issues 17: 61-64, 66-68, 99, 2003.
33. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ: Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 61: 305-316, 2002.
34. Little MA, O'Riordan A, Lucey B, Farrell M, Lee M, Conlon PJ, Walshe JJ: A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters. Nephrol Dial Transplant 16: 2194-2200, 2001.
35. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK: Type of vascular access and mortality in US hemodialysis patients. Kidney Int 60: 1443-1451, 2001.
36. Block GA: Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 10: 741-747, 2001.
37. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35: 1226-1237, 2000.
38. Qunibi WY: Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int (Supl.: S8-S12), 2004.
39. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1- 201, 2003.
40. Locatelli F: The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant 19 (Supl. 5): V15-19, 2004.
41. Berend K, Van der Voet G, Boer WH: Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe. Kidney Int 59: 746-753, 2001.
42. Española RF: Agua para dilución de disoluciones concentradas para hemodiálisis. Real Farmacopea Española: 357-377, 1997.
43. Tielemans C, Hoenich NA, Levin NW, Lonnemann G, Favero MS, Schiffl H: Are standards for dialysate purity in hemodialysis insufficiently strict? Semin Dial 14: 328-336, 2001
44. Schiffl H, Lang SM, Stratakis D, Fischer R: Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 16: 1863-1869, 2001.
45. Pérez García R, Ceballos F, Escallada R, Gómez-Reino MI, Martín-Rabadán P, Pérez García A, Ramírez Cahmond R, Sobrino PE, Solazábal C: Gestión de la calidad del líquido de diálisis. Nefrología 1-42, 2004.
46. Hoenich NA, Levin R: The implications of water quality in hemodialysis. Semin Dial 16: 492-497, 2003.
47. Lonnemann G: The quality of dialysate: an integrated approach. Kidney Int (Supl. 76): S112-119, 2000.
48. Barril G, González Parra E, Alcázar R, Arenas D, Campistol JM, Caramelo C, Carrasco M, Carreno V, Espinosa M, García Valdecasas J, Górriz JL, López MD, Martín L, Ruiz P, Terruel JL: Guías sobre enfermedades víricas en hemodiálisis (HD). Nefrología 24 (Supl. 2): 43-66, 2004.